TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00651794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teamwork training
Description: Crew Resource Management (CRM) is an aviation training program mandated for all crew members that teaches human factors concepts, communication skills, and teamwork behaviors that can prevent and manage error. Over the last six years the study team has translated these behaviors to neonatal resuscitation and demonstrated that they can be reliably measured. Adding teamwork instruction to the existing NRP, based upon CRM, may be a method to improve communication, teamwork, and the overall quality of neonatal resuscitation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teamwork training
Description: Crew Resource Management (CRM) is an aviation training program mandated for all crew members that teaches human factors concepts, communication skills, and teamwork behaviors that can prevent and manage error. Over the last six years the study team has translated these behaviors to neonatal resuscitation and demonstrated that they can be reliably measured. Adding teamwork instruction to the existing NRP, based upon CRM, may be a method to improve communication, teamwork, and the overall quality of neonatal resuscitation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard NRP curriculum
Description: The existing NRP course, taught to most caregivers in the United States who care for newborns, focuses on teaching the technical aspects of neonatal resuscitation with little attention paid to communication and teamwork.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard NRP curriculum
Description: The existing NRP course, taught to most caregivers in the United States who care for newborns, focuses on teaching the technical aspects of neonatal resuscitation with little attention paid to communication and teamwork.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard NRP curriculum
Description: The existing NRP course, taught to most caregivers in the United States who care for newborns, focuses on teaching the technical aspects of neonatal resuscitation with little attention paid to communication and teamwork.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Skills practice with low-fidelity mannequin
Study: NCT03983850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan should be administered intravenously via a central venous catheter as a three-hour infusion every 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan should be administered intravenously via a central venous catheter as a three-hour infusion every 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan should be administered intravenously via a central venous catheter as a three-hour infusion every 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan should be administered intravenously via a central venous catheter as a three-hour infusion every 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be infused by IV over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be infused by IV over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be infused by IV over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be infused by IV over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be infused by IV over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV cyclophosphamide will be administered over 2 hours. Slower rates of infusion may be used to decrease side effects. A fluid intake of greater than 2 L/day is recommended during and for 1 to 2 days after cyclophosphamide administration.
Study: NCT00651794

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills practice with low-fidelity mannequin

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills practice with high-fidelity mannequin
Description: SimBaby mannequins (Laerdal Medical Corp, Stavanger, Norway) were used in the high-fidelity skills stations. These mannequins have simulated heart tones, breath sounds, pulses, and cries.
Study: NCT03269864

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perforator flaps
Description: 40 patients with post traumatic skin defect at leg and foot will be managed by perforator flaps, 20 with pedicled perforator flaps and other 20 with free perforator flaps

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: perforator flaps
Description: 40 patients with post traumatic skin defect at leg and foot will be managed by perforator flaps, 20 with pedicled perforator flaps and other 20 with free perforator flaps
Study: NCT04011267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy by foot-ankle segmental and functional exercises
Description: The physiotherapeutic foot-ankle exercise protocol is based on previous clinical trials. It was designed following three criteria established in a supervised, face-to-face intervention: muscle stretching; strengthening of the intrinsic muscles; and strengthening of the extrinsic foot-ankle muscles and functional exercises, such as balance and gait training. To avoid monotony, game principles were inserted to reward the exercise execution and enhance motivation. The exercises change from session to session, and the maximum duration is no longer than 20 minutes. The exercises should only be done 3 times/week; no more than eight exercises each day; and the individual difficulty is regulated by the effort scale to manage the customized progression. In total, 39 different exercises were chosen, and when including their sublevels of progression, a total of 104 different exercises can be completed.
Study: NCT00612690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community mental health consultation model program
Description: The community mental health consultation model program included collaboration among community mental health providers and (1) parent advocates to effectively maintain families in a school-based mental health program, (2) classroom teachers to enhance children's academic performance, and (3) peer-identified influential teachers to influence classroom teachers' use of behavior management strategies. This model further focused on the strongest teacher and parent predictors of student learning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: TAU included referral to community mental health clinic-based services, where participants received standard care for mental health-related problems.
Study: NCT03356990

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant Starch
Description: Dietary supplement will be taken every day for total of 2 weeks. Each participant will be take half the dose (one bag) of Hi-Maze 260 or High RS Gummy Chews in the morning and the other half dose (one bag) in the evening.
Study: NCT03548103

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green tea extract
Description: Green tea extract 500 mg tid for 16 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tid for 16 weeks
Study: NCT04111718

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Platelet-rich plasma (PRP)
Description: Autologous platelet-rich plasma which will be derived from blood drawn from the patient.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Description: Autologous platelet-rich plasma which will be derived from blood drawn from the patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Viewing of preparation
Description: The patient will receive a description of the preparation process and will view the preparation in the centrifuge.
Study: NCT02879643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marqibo
Description: The focus of the study design and statistical analysis is to determine whether Marqibo® can be substituted for standard vincristine and successfully administered to patients with relapsed ALL in three different treatment cohorts: (A) treatment with the UK ALL R3 regimen; (B) treatment with UK ALL R3 regimen without mitoxantrone, and (C) treatment with ALL maintenance therapy. Secondary objectives include estimating rates of serious toxicities and therapy delays in each of these cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marqibo
Description: The focus of the study design and statistical analysis is to determine whether Marqibo® can be substituted for standard vincristine and successfully administered to patients with relapsed ALL in three different treatment cohorts: (A) treatment with the UK ALL R3 regimen; (B) treatment with UK ALL R3 regimen without mitoxantrone, and (C) treatment with ALL maintenance therapy. Secondary objectives include estimating rates of serious toxicities and therapy delays in each of these cohorts.
Study: NCT02358005

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy 120mj

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: non extracorporeal shock wave therapy
Study: NCT02879643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marqibo
Description: The focus of the study design and statistical analysis is to determine whether Marqibo® can be substituted for standard vincristine and successfully administered to patients with relapsed ALL in three different treatment cohorts: (A) treatment with the UK ALL R3 regimen; (B) treatment with UK ALL R3 regimen without mitoxantrone, and (C) treatment with ALL maintenance therapy. Secondary objectives include estimating rates of serious toxicities and therapy delays in each of these cohorts.
Study: NCT00722722

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Velcade given in four-dose cycles intravenously (through a vein).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Velcade given in four-dose cycles intravenously (through a vein).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Velcade given in four-dose cycles intravenously (through a vein).
Study: NCT03939962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1210 combined with FOLFOX
Description: 1. SHR1210, iv, 200 mg d1, 30-minute intravenous infusion, repeated every 14 days.~2. FOLFOX: Oxaliplatin 85mg/m2 ivgtt 2h d1; 5-fluorouracil 400mg/m2 iv d1; leucovorin 400mg/m2 ivgtt 2h d1,5-fluorouracil 2400mg/m2 CIV 46h, repeated every 14 days Patients who have no disease progression and can tolerate surgery receive surgery. When the investigator believes that the patient is not suitable for continued medication or according to the RECIST 1.1 standard, the evaluation is PD and the medication is over. The PD-1 monoclonal antibody does not allow for reductions and can only delay or suspend medication.
Study: NCT00663884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitiglinide
Description: mitiglinide 10mg three times a day before a meal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voglibose
Description: voglibose 0.2mg three times a day before a meal
Study: NCT00753090

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vanguard™ Deep Dish Rotating Platform Knee
Description: Total knee replacements with the Vanguard Deep Dish Rotating Platform Knee

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vanguard™ Cruciate Retaining Knee
Description: Total knee replacements with the Vanguard Cruciate Retaining Knee
Study: NCT03103321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive Knowing your Options decision aid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive Knowing your Options decision aid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive Prostate Choice decision aid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive Prostate Choice decision aid

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Undergo usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06659965

Intervention type: DRUG
Intervention: Intravenous Methocarbamol
Description: At least 500 mg of intravenous methocarbamol administered within 2 hours after the end of elective spine surgery for acute postoperative pain management
Study: NCT06659237

Intervention type: DIAGNOSTIC_TEST
Intervention: 16s rRNA or shotgun metagenomics
Description: 16s rRNA or shotgun metagenomics on oral and fecal samples

Intervention type: DIAGNOSTIC_TEST
Intervention: 16s rRNA or shotgun metagenomics
Description: 16s rRNA or shotgun metagenomics on oral and fecal samples
Study: NCT00772915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Dose: -40 mg once weekly (days 1, 8, 15, \& 22) orally with food until progression.~If after 3 cycles, a partial response is not achieved on lenalidomide alone, dexamethasone 10 mg weekly will be added, and the weekly dexamethasone dose will be increased by 10 mg each cycle to a maximum of 40 mg weekly, as long as a partial response is not achieved. If a partial response is achieved at a dose of dexamethasone less than 40 mg weekly, patients will continue on that dose. If progression at any time, increase dexamethasone to 40 mg weekly. Patient will go off study only when progression is documented while receiving 40 mg/week of dexamethasone or the maximum tolerated dose of dexamethasone (if prior dose reductions have been implemented for toxicity). Increases in dexamethasone dose are to be made only at the initiation of a cycle.~If progression at any time while on lenalidomide alone (first 3 cycles), add dexamethasone 40 mg weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: 25mg once daily orally with food on days 1-21 of 28 day cycle until progression or to a maximum of 18 cycles.~Lenalidomide alone will be administered for the first 3 cycles, then in combination with dexamethasone as needed (described).
Study: NCT04383184

Intervention type: PROCEDURE
Intervention: tracheoplasty
Description: tracheoplasty and only left pulmonary artery transplantation

Intervention type: PROCEDURE
Intervention: tracheoplasty
Description: tracheoplasty and only left pulmonary artery transplantation
Study: NCT00211757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Description: Study drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator.
Study: NCT04669262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-DXP604
Description: Administered as intravenous (IV) infusion over 30 to 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-DXP604
Description: Administered as intravenous (IV) infusion over 30 to 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-DXP593
Description: Administered as intravenous (IV) infusion over 30 to 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match BGB-DXP593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match BGB-DXP604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match BGB-DXP604
Study: NCT02483091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifaceted KT intervention
Description: The intervention consists of three webinars followed by the quiz, two online case scenario and a video on BAP model plus a printed copy of Clinical Practice Guideline (CPGs) on NSNP.~After completing these modules and learning the key strategies, each chiropractor will recruit five neck pain patients and implement the strategies on their patients to measure the clinical outcomes for a follow-up of three months.~The control group will receive only a printed copy of CPGs. A checklist of proxy measures embedded within patient encounter forms will be used to assess chiropractors' compliance with guideline recommendations at study onset and at three months.
Study: NCT02860208

Intervention type: PROCEDURE
Intervention: 3 years follow-up
Description: Examination 3 years after surgical treatment of peri-implantitis
Study: NCT01198210

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: local peritonsillar infiltration of 2 ml saline,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: local peritonsillar infiltration of ketamine (0.5 mg/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: local peritonsillar infiltration dexamethasone (0.2 mg/kg))

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine-dexamethasone
Description: local peritonsillar infiltration combination of ketamine0.5mg/kg-dexamethason 0.2mg/kg
Study: NCT02326168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin (BCG)
Description: Intravesical instillation for non-muscle invasive bladder cancer
Study: NCT02461290

Intervention type: RADIATION
Intervention: Chemotherapy

Intervention type: DRUG
Intervention: Rituximab
Study: NCT01304992

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein drink - low dosage
Description: The subjects will consume 500 mL of a protein drink containing 25 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein drink - low dosage
Description: The subjects will consume 500 mL of a protein drink containing 25 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein drink - high dosage
Description: The subjects will consume 500 mL of a protein drink containing 40 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein drink - high dosage
Description: The subjects will consume 500 mL of a protein drink containing 40 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.
Study: NCT02709551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HRV_Bfb

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBI

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MBI_HRV_Bfb
Study: NCT01848977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vascular occlusion test
Description: Using Invos® probe attacted to one thenar muscle, tissue oxgyenation is measured by VOT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vascular occlusion test
Description: Using Inspectra™ probe attacted to another thenar muscle, tissue oxgyenation is measured by VOT.
Study: NCT00493324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alefacept
Description: Intramuscular
Study: NCT01660672

Intervention type: DRUG
Group type: OTHER
Intervention: LEVETIRACETAM
Description: liquid, 40 mg/kg loading dose and 30mg/kg every 12 hours via nasogastric tube for 3 days--this is standard dose. If primary outcome is not reached, dose escalation to 150, 225, and 300% standard, as needed, will be conducted.
Study: NCT04153175

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: ICV delivery of CT-010 via an implantable pump and a cranial port and dual lumen catheter (CIC)
Description: Subjects will be implanted with a drug delivery pump and catheters leading to the ICV space allowing delivery of CT-010.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo delivery via an implantable pump and a cranial port and dual lumen catheter (CIC)
Description: Subjects will be implanted with a drug delivery pump and catheters leading to the ICV space allowing delivery of a placebo (saline).
Study: NCT03103321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00969592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glulisine, insulin aspart
Description: single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during second euglycemic glucose clamp

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart, insulin glulisine
Description: single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during second euglycemic glucose clamp